Annals of Coloproctology

Original Article

Malignant disease, Rectal cancer

The Use of M2-Pyruvate Kinase as a Stool Biomarker for Detection of Colorectal Cancer in Tertiary Teaching Hospital: A Comparative Study: Shahidah Che Alhadi, Wan Zainira Wan Zain, Zalina Zahari, Mohd Nizam Md Hashim, Syed Hassan Syed Abd. Aziz, Zaidi Zakaria, Michael Pak-Kai Wong, Andee Dzulkarnaen Zakaria; Ann Coloproctol. 2020;36(6):409-414. Published online September 18, 2020; DOI: https://doi.org/10.3393/ac.2020.08.27

6,437 View
109 Download
10 Web of Science
9 Citations

Purpose
Guaiac fecal occult blood test (gFOBT) has been the standard for colorectal screening but it has low sensitivity and specificity. This study evaluated the use of fecal tumor M2-pyruvate kinase (M2-PK) for detection of colorectal cancer and to compare with the current surveillance tool; gFOBT in symptomatic adult subjects underwent colonoscopy.
Methods
Stool samples were collected prospectively from symptomatic adults who had elective colonoscopy from September 2014 to January 2016 and were analyzed with the ScheBo M2-PK Quick test and laboratory detection of fecal hemoglobin.
Results
The results were correlated to the colonoscopy findings and/or histopathology report. Eighty-five subjects (age of 56.8 ± 15.3 years [mean ± standard deviation]) were recruited with a total of 17 colorectal cancer (20.0%) and 10 colorectal adenoma patients (11.8%). The sensitivity of M2-PK test in colorectal cancer detection was higher than gFOBT (100% vs. 64.7%). M2-PK test had a lower specificity when compared to gFOBT (72.5% vs. 88.2%) in colorectal cancer detection. The positive and negative predictive values were 47.2% and 100% for M2-PK test and 57.9% and 90.9% for gFOBT.
Conclusion
Fecal M2-PK Quick test has a high sensitivity for detection of colorectal cancer when compared to gFOBT, making it the potential choice for colorectal tumor screening biomarker in the future.

Citations

Citations to this article as recorded by

The Importance of Evaluating Serum Levels of Tumor Markers M2-PK and Inhibin A in Patients Undergoing Colonoscopy
Mahmood Khosravi, Ali Arash Anoushirvani, Zahedin Kheiri, Ali Rahbari, Ali Jadidi
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Noninvasive fecal testing for colorectal cancer
Jianhua Zou, Zhanshuo Xiao, Yu Wu, Jingyan Yang, Ning Cui
Clinica Chimica Acta.2022; 524: 123. CrossRef
Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis
Atefeh Nasir Kansestani, Mohammad Erfan Zare, Qingchao Tong, Jun Zhang
Scientific Reports.2022;[Epub] CrossRef
Direction of diagnosis and treatment improvement in colorectal cancer
In Ja Park
Journal of the Korean Medical Association.2022; 65(9): 540. CrossRef
Epidemiology, risk factors, and prevention of colorectal cancer
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
Journal of the Korean Medical Association.2022; 65(9): 549. CrossRef
Epidemiology, Risk Factors, and Prevention of Colorectal Cancer-An English Version
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 231. CrossRef
Update on Diagnosis and Treatment of Colorectal Cancer
Chan Wook Kim
The Ewha Medical Journal.2022;[Epub] CrossRef
Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review
Allegra Ferrari, Isabelle Neefs, Sarah Hoeck, Marc Peeters, Guido Van Hal
Cancers.2021; 13(8): 1820. CrossRef
Genotypic and Phenotypic Characteristics of Hereditary Colorectal Cancer
Jin Cheon Kim, Walter F. Bodmer
Annals of Coloproctology.2021; 37(6): 368. CrossRef

First
Prev
Page of 1
Next
Last

Search